| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579473 | EXELIXIS | c-Met modulators and methods of use |
Aug, 2026
(2 years from now) | |
| US11091439 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US8877776 | EXELIXIS | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11091440 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US11098015 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US11298349 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(7 years from now) | |
| US9717720 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(7 years from now) | |
Cometriq is owned by Exelixis.
Cometriq contains Cabozantinib S-Malate.
Cometriq has a total of 7 drug patents out of which 0 drug patents have expired.
Cometriq was authorised for market use on 29 November, 2012.
Cometriq is available in capsule;oral dosage forms.
Cometriq can be used as method of treating medullary thyroid cancer.
Drug patent challenges can be filed against Cometriq from 29 November, 2016.
The generics of Cometriq are possible to be released after 10 February, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-33) | Nov 29, 2019 |
| Orphan Drug Exclusivity(ODE) | Nov 29, 2019 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 29 November, 2012
Treatment: Method of treating medullary thyroid cancer
Dosage: CAPSULE;ORAL
COMETRIQ family patents
